Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5



Kushner, Robert F, Calanna, Salvatore, Davies, Melanie, Dicker, Dror, Garvey, W Timothy, Goldman, Bryan, Lingvay, Ildiko, Thomsen, Mette, Wadden, Thomas A, Wharton, Sean
et al (show 2 more authors) (2020) Semaglutide 2.4 mg for the Treatment of Obesity: Key Elements of the STEP Trials 1 to 5. OBESITY, 28 (6). 1050 - 1061.

[img] Text
Kushner STEP_trials_MainDocument_with figures.docx - Accepted Version

Download (277kB)
Item Type: Article
Depositing User: Symplectic Admin
Date Deposited: 01 Jun 2020 10:17
Last Modified: 23 Jan 2021 05:11
DOI: 10.1002/oby.22794
Related URLs:
URI: https://livrepository.liverpool.ac.uk/id/eprint/3089265